Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution

Not Applicable

Completed

Conditions: Adverse Effect of Contact Lens Solution

Interventions: Device: Bausch & Lomb Multipurpose Solution
Device: Alcon OptiFree Replenish Multipurpose Solution

First Posted Date: 2008-03-14

Last Posted Date: 2011-12-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 361

Registration Number: NCT00636194

Locations: 🇲🇾
Laser Focus Sdn Bhd, Vision Correction Centre, Jalan Kuning, Tamn Pelangi, Johor Bahru, Malaysia

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

Phase 2

Completed

Conditions: Bacterial Conjunctivitis

Interventions: Drug: Vehicle
Drug: ISV-403

First Posted Date: 2008-02-25

Last Posted Date: 2015-03-24

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 270

Registration Number: NCT00622908

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Phase 2

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Latanoprost 0.005%
Drug: PF-03187207
Drug: Latanoprost Vehicle
Drug: PF-03187207 Vehicle

First Posted Date: 2008-01-16

Last Posted Date: 2020-09-14

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 117

Registration Number: NCT00595101

Locations: 🇯🇵
Pfizer Investigational Site, Shizuoka, Japan

Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Bepreve
Drug: Placebo

First Posted Date: 2008-01-04

Last Posted Date: 2013-02-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 861

Registration Number: NCT00586625

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

Phase 3

Completed

Conditions: Allergic Conjunctivitis

Interventions: Drug: Bepotastine Besilate Ophthalmic Solution 1.0%
Drug: placebo comparator
Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%

First Posted Date: 2008-01-04

Last Posted Date: 2013-02-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 130

Registration Number: NCT00586664

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Efficacy and Safety of Bromfenac Ophthalmic Solution

Phase 2

Completed

Conditions: Cataract Surgery

Interventions: Drug: bromfenac ophthalmic solution

First Posted Date: 2008-01-04

Last Posted Date: 2013-02-15

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 568

Registration Number: NCT00585975

Locations: 🇺🇸
ISTA Pharmaceuticals, Inc., Irvine, California, United States

Safety and Efficacy of Intravitreal Fluocinolone Acetonide Implants in Patients With Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: 0.59 mg fluocinolone acetonide intravitreal implant
Drug: 2.1 mg fluocinolone acetonide intravitreal implant
Procedure: standard of care laser photocoagulation

First Posted Date: 2007-12-19

Last Posted Date: 2011-12-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 40

Registration Number: NCT00576459

Locations: 🇮🇳
LV Prasad Eye Institute, Banjara Hills, Hyderabad, India
🇨🇳
The Chinese University of Hong Kong, Hong Kong, China

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye

Phase 2

Completed

Conditions: Dry Eye

Interventions: Drug: loteprednol etabonate ophthalmic suspension, 0.5%
Drug: vehicle of loteprednol etabonate

First Posted Date: 2007-11-20

Last Posted Date: 2011-07-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 119

Registration Number: NCT00560638

Locations: 🇺🇸
Ophthalmic Research Associates, Andover, Massachusetts, United States

Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex

Phase 4

Completed

Conditions: Inflammation

Interventions: Drug: Loteprednol etabonate 0.5% and tobramycin 0.3%
Drug: Dexamethasone 0.1% and tobramycin 0.3%

First Posted Date: 2007-09-21

Last Posted Date: 2011-12-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 310

Registration Number: NCT00532961

Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Procedure: Standard of Care
Drug: fluocinolone acetonide

First Posted Date: 2007-07-17

Last Posted Date: 2013-11-28

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 196

Registration Number: NCT00502541

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy